One possible explanation is that patients who were immunologically compensated (particularly when using HAART), i.e. with high levels of CD4 lymphocytes, are more liable to have traditional metabolic complications such as obesity, metabolic syndrome and hypertension and, consequently, a higher risk of presenting subclinical atherosclerosis [37,38]. Here, CD4 is linked to atherosclerosis.